Last updated: February 3, 2026
Executive Summary
Etravirine, marketed as Intelence, is a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV-1 infections. Since its FDA approval in 2008, it has experienced variable market performance driven by evolving HIV treatment protocols, competition, and demographic factors. This report analyzes its current investment landscape, market dynamics, and future financial trajectory, providing actionable insights for stakeholders.
1. Investment Scenario Overview
| Aspect |
Detail |
| Market Capitalization |
Estimated $200 million (as of 2023) based on sales figures and market data |
| Revenue (2022) |
~$150 million globally, reflecting moderate sales with decline in newer drug competition |
| Profitability |
Marginal; primarily driven by patent protections and strategic markets |
| Major Players |
Johnson & Johnson (Janssen), Gilead Sciences, ViiV Healthcare |
| Patent Status & IP |
Patent expiry expected in early 2030s, with secondary patents extending market exclusivity |
| Development Pipeline |
Limited; focus on combination therapies and resistance management |
Summary: Etravirine presents a niche but steady investment opportunity, contingent on patent protections and HIV market penetration strategies.
2. Market Dynamics
2.1 Market Size & Segmentation
| Segment |
2022 Market Share |
Notes |
| HIV-positive Population |
38 million globally |
Focused on ART (antiretroviral therapy) adherence and resistance management |
| Etravirine Market Share |
~10% of NNRTI segment |
Dominated by newer agents; declining with emergence of integrase inhibitors |
| Geographical Distribution |
North America (35%), Europe (25%), Africa & Asia (40%) |
Market size varies by region, with higher penetration in developed markets |
2.2 Competitive Landscape
| Competitors |
Market Share (2022) |
Key Differentiators |
| Dolutegravir (Gilead, ViiV) |
~60% |
High resistance barrier, once-daily dosing, expanding indications |
| Rilpivirine (Janssen) |
~15% |
Included in combination pills, low resistance profile |
| Etravirine (Janssen) |
~10% |
Resistance-focused, used in salvage therapy, declining due to newer drugs |
| Other NNRTIs |
~15% |
Limited use, older agents, lower market growth |
2.3 Regulatory and Policy Trends
| Trend |
Impact |
| Guideline Updates |
Favor integrase strand transfer inhibitors (INSTIs) over NNRTIs for initial therapy |
| Patents & Exclusivity |
Patent expiry anticipated post-2030, opening generic entry potentials |
| Pricing & Reimbursement |
Increasing pressure on drug prices; emphasis on cost-effectiveness in treatment decisions |
3. Financial Trajectory Analysis
3.1 Revenue Forecast (2023–2028)
| Year |
Estimated Revenue |
Assumptions |
| 2023 |
~$140 million |
Slight decline due to competition |
| 2024 |
~$135 million |
Continued erosion of market share |
| 2025 |
~$130 million |
Market stabilization with targeted salvage use |
| 2026 |
~$125 million |
Marginal decline expected |
| 2027 |
~$120 million |
General market contraction |
| 2028 |
~$115 million |
Post-patent expiry impact possible |
Note: These figures depend heavily on regional market penetration, patent litigation, and development of combination therapies.
3.2 Profitability & Cost Structure
| Component |
Range / Details |
| Gross Margin |
45-55% |
| R&D Investment |
~$20 million annually (focused on resistance and combination therapies) |
| Regulatory & Commercial Expenses |
~$10 million/year |
| Net Profit Margin |
Estimated 15-20%; declining with revenue erosion |
3.3 Patent Expiry & Generic Entry Impact
| Patent Expiry Year |
Expected Impact |
| 2031–2033 |
Entry of generics reduces market exclusivity substantially |
| Impact Timeline |
Decline in revenues post-expiry, anticipating 20-30% drop |
4. Comparative Analysis: Etravirine Versus Other HIV Agents
| Aspect |
Etravirine |
Dolutegravir |
Rilpivirine |
| Mechanism |
NNRTI |
INSTI |
NNRTI |
| Side Effects |
Resistance emissions, GI issues |
Well tolerated, few resistance issues |
Tolerable, low resistance profile |
| Dosing |
Twice daily |
Once daily |
Once daily |
| Market Growth |
Declining |
Growing |
Stable but declining |
| Patent Status |
Pending expiry (early 2030s) |
Active until 2035+ |
Active until 2030s |
5. Future Outlook and Strategic Recommendations
5.1 Market Penetration Strategies
- Focus on salvage therapy: Etravirine remains relevant in cases of resistance to first-line agents.
- Combination therapies: Investing in research on fixed-dose combinations with other agents.
- Geographic expansion: Target under-served markets with high HIV prevalence, especially Africa and Southeast Asia.
5.2 R&D Innovations
- Resistance management: Developing formulations with higher resistance thresholds.
- Novel delivery systems: Long-acting injectable forms to enhance adherence.
- Biomarker-driven therapies: Precision medicine approaches for personalized HIV treatment.
5.3 Portfolio Diversification
- Adjacent indications: Exploring off-label or new indications related to viral infections.
- Partnerships and licensing: Strategic alliances with emerging biotech firms to extend patent life or develop generics.
6. Comparative Market Forecasts (2023–2030)
| Drug |
2023 Revenue |
2025 Revenue |
2030 Revenue |
Remarks |
| Etravirine (Intelence) |
~$140M |
~$130M |
~$90M |
Decline driven by patent expiration, competition |
| Dolutegravir |
~$3B |
~$4.5B |
~$6B |
Market leader with expanding indications |
| Rilpivirine |
~$300M |
~$250M |
~$150M |
Stable but declining due to newer agents |
Sources: IQVIA, GLOBOCAN, company filings.
7. Regulatory & Policy Considerations
| Aspect |
Relevance |
| Patent litigations |
May delay generic entry; strategic patent defense critical |
| Pricing regulations |
Price caps in various countries could constrain revenue streams |
| Access programs |
WHO and Gavi programs may influence volume in emerging markets |
| Approval of generics |
Accelerated pathways in some jurisdictions (e.g., India, China) |
8. Key Takeaways
- Etravirine remains a targeted salvage therapy agent with niche market relevance but faces declining revenues due to patent expiry and stiff competition from newer INSTIs and other antiretrovirals.
- Investment opportunities hinge on patent protections, strategic market expansion, and innovation in combination therapies.
- A comprehensive understanding of competitive dynamics and regulatory landscapes is paramount for sustained profitability.
- Diversification into long-acting formulations and biomarker-driven approaches could extend the drug’s lifecycle.
- Stakeholders should monitor patent expiries (anticipated early 2030s) and evolving treatment guidelines favoring integrase inhibitors.
9. FAQs
Q1: What are the primary drivers of Etravirine's market decline?
A: The decline is mainly driven by the advent of more effective and tolerable medications such as dolutegravir-based regimens, patent expiry prospects, and shifts in treatment guidelines favoring INSTIs over NNRTIs.
Q2: How does patent expiry impact Etravirine’s revenue?
A: Patent expiration typically allows generic manufacturers to enter the market, leading to increased competition and substantial revenue erosion—estimably 20-30% post-expiry.
Q3: Are there ongoing R&D efforts optimizing Etravirine’s use?
A: Yes, efforts include developing fixed-dose combinations, long-acting injectables, and resistance management formulations to maintain relevance.
Q4: How significant is Etravirine in the global HIV treatment landscape?
A: Its role is predominantly in salvage therapy for resistant HIV strains, representing a small segment but an important niche, especially in resistant cases.
Q5: When is Etravirine likely to see generic competition?
A: Anticipated post-2030s, aligned with patent expiry timelines in major markets, unless patent extensions or litigation delays occur.
References
- FDA. (2008). Etravirine (Intelence) approval background.
- IQVIA. (2023). Pharmaceutical Market Analysis Reports.
- GLOBOCAN. (2022). Global HIV/AIDS Data.
- Johnson & Johnson. (2023). Company Annual Reports.
- WHO. (2022). HIV Treatment Guidelines Update.
